BLI Banque de Luxembourg Investments Acquires Shares of 124,400 The Cooper Companies, Inc. (NASDAQ:COO)

BLI Banque de Luxembourg Investments bought a new stake in The Cooper Companies, Inc. (NASDAQ:COO - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 124,400 shares of the medical device company's stock, valued at approximately $11,371,000. BLI Banque de Luxembourg Investments owned approximately 0.06% of Cooper Companies as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Byrne Asset Management LLC acquired a new stake in Cooper Companies during the 4th quarter worth $33,000. OFI Invest Asset Management acquired a new position in shares of Cooper Companies in the fourth quarter valued at approximately $34,000. New Age Alpha Advisors LLC bought a new stake in shares of Cooper Companies during the fourth quarter worth $38,000. Covestor Ltd lifted its position in Cooper Companies by 35.5% in the 4th quarter. Covestor Ltd now owns 458 shares of the medical device company's stock valued at $42,000 after acquiring an additional 120 shares in the last quarter. Finally, West Financial Advisors LLC acquired a new position in Cooper Companies in the 4th quarter worth $49,000. 24.39% of the stock is owned by institutional investors.

Analysts Set New Price Targets

COO has been the topic of a number of research reports. Citigroup cut their price target on Cooper Companies from $115.00 to $110.00 and set a "buy" rating on the stock in a report on Friday, March 7th. Robert W. Baird lowered their price objective on shares of Cooper Companies from $117.00 to $107.00 and set an "outperform" rating on the stock in a report on Friday, March 7th. Needham & Company LLC restated a "hold" rating on shares of Cooper Companies in a report on Friday, March 7th. Stifel Nicolaus cut their price target on shares of Cooper Companies from $115.00 to $105.00 and set a "buy" rating on the stock in a research report on Friday, March 7th. Finally, Piper Sandler restated an "overweight" rating and set a $115.00 price objective (down from $120.00) on shares of Cooper Companies in a research note on Friday, March 7th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $110.25.

Cooper Companies Stock Performance

NASDAQ:COO traded up $0.68 on Wednesday, hitting $81.25. The company's stock had a trading volume of 1,412,840 shares, compared to its average volume of 1,439,552. The Cooper Companies, Inc. has a one year low of $69.81 and a one year high of $112.38. The firm has a market capitalization of $16.25 billion, a P/E ratio of 41.67, a price-to-earnings-growth ratio of 2.25 and a beta of 1.08. The stock has a fifty day moving average of $81.06 and a two-hundred day moving average of $91.42. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32.

Cooper Companies (NASDAQ:COO - Get Free Report) last posted its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, meeting analysts' consensus estimates of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The business had revenue of $964.70 million for the quarter, compared to analysts' expectations of $981.25 million. Research analysts predict that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.